Literature DB >> 3838737

Plasma kinetics and effects of 5,6-dihydro-5-azacytidine in mice and L1210 tumor.

D S Zaharko, J M Covey, J A Kelley.   

Abstract

The plasma kinetics of 5,6-dihydro-5-azacytidine (DHAC) was determined in mice using an HPLC method following an intravenous dose of 2000 mg/kg (LD10). Pharmacokinetic parameters calculated from these single dose data were sufficient to predict steady state plasma concentrations produced by s.c. infusion of DHAC. Lethal toxicity (LD66) occurred at an infusion rate of 37 mg/kg/h (111mg/m2/h), corresponding to a plasma steady-state DHAC concentration 38 +/- 14 micrograms/ml when the infusion time was 96 h; no lethality occurred at infusion times of 72 h or less. In vitro clonogenic assays and in vivo therapeutic experiments with L1210 tumor indicated that increasing the exposure time at concentrations near 25 micrograms/ml from 24 to 72 h increased the cell kill only slightly. The maximum log cell kill of L1210 estimated from either in vitro or in vivo data was 1.5 logs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838737     DOI: 10.1007/bf00176822

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  9 in total

1.  EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA.

Authors:  H E SKIPPER; F M SCHABEL; W S WILCOX
Journal:  Cancer Chemother Rep       Date:  1964-02

2.  Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations.

Authors:  F Theeuwes; S I Yum
Journal:  Ann Biomed Eng       Date:  1976-12       Impact factor: 3.934

3.  Comparison of the in vitro cytotoxicity (L1210) of 5-aza-2'-deoxycytidine with its therapeutic and toxic effects in mice.

Authors:  J M Covey; D S Zaharko
Journal:  Eur J Cancer Clin Oncol       Date:  1985-01

4.  Effects of 5-aza-2'-deoxycytidine in combination with the biochemical modulator thymidine or the immune modulator pyran copolymer on L1210 leukemia-bearing mice.

Authors:  D S Zaharko; J M Covey
Journal:  Cancer Treat Rep       Date:  1984-10

5.  A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880).

Authors:  G A Curt; J A Kelley; R L Fine; P N Huguenin; J S Roth; G Batist; J Jenkins; J M Collins
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

6.  Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.

Authors:  J A Beisler; M M Abbasi; J A Kelley; J S Driscoll
Journal:  J Med Chem       Date:  1977-06       Impact factor: 7.446

7.  Effect of intravenous infusion of 5-aza-2'-deoxycytidine on survival time of mice with L1210 leukemia.

Authors:  R L Momparier; F A Gonzales
Journal:  Cancer Res       Date:  1978-09       Impact factor: 12.701

8.  Contrasting cytotoxicity kinetics of 5-azacytidine and dihydro-5-azacytidine hydrochloride in L1210 leukemia in mice.

Authors:  C A Presant; D Coulter; F Valeriote; T J Vietti
Journal:  J Natl Cancer Inst       Date:  1981-06       Impact factor: 13.506

9.  Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydro-5-azacytidine.

Authors:  P Voytek; J A Beisler; M M Abbasi; M K Wolpert-DeFilippes
Journal:  Cancer Res       Date:  1977-07       Impact factor: 12.701

  9 in total
  1 in total

1.  Arabinosyl-5-azacytosine: plasma kinetics and therapeutic response (L1210) in vitro and in vivo in mice.

Authors:  D S Zaharko; J M Covey
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.